Abstract
Backround Capsule colonoscopy might present an alternative to colonoscopy for colorectal neoplasia screening. Aim To assess the accuracy of second-generation capsule colonoscopy (CCE2) for colorectal neoplasia detection compared with conventional colonoscopy (CC). Methods From 2011–2015, we performed a multicenter, prospective, cross-over study evaluating the use of CCE2 as a possible colorectal cancer (CRC) screening test based on the assessment of the method's characteristics (accuracy) and safety and patient acceptance of the routine. Enrolled participants fulfilled the CRC screening population criteria if they were asymptomatic, were older than 50, and had no personal or familial history of colorectal neoplasia. The primary outcome was accuracy for the detection of polyps ≥ 6 mm. Secondary outcomes were accuracy for all polyps, polyps ≥ 10 mm, adenomas ≥ 10 mm, and cancers, the quality of bowel cleansing, safety, and CCE2 acceptability by the screening population. Results A total of 236 individuals were examined; 11 patients (5%) were excluded. Therefore, 225 subjects (95%) were considered in the intention-to-screen (ITS) group. A total of 201 patients (89%) completed both examinations successfully (per protocol group). In the ITS group, polyps were diagnosed during CC in 114 subjects (51%); polyps ≥ 6 mm, polyps ≥ 10 mm, and adenomas ≥ 10 mm were diagnosed in 34 (15%), 16 (7%), and 11 (5%) patients, respectively. The sensitivity of CCE2 for polyps ≥ 6 mm, polyps ≥ 10 mm, and adenomas ≥ 10 mm was 79% (95% confidence interval (CI): 62–91%), 88% (95% CI: 62–98%), and 100% (95% CI: 72–100%), respectively. Conclusion Second-generation capsule colonoscopy is a safe, noninvasive, and sensitive method for colorectal neoplasia detection although CC remains the preferred method for considerable proportion of subjects. CCE2 may therefore be accepted as the primary screening test for colorectal cancer screening.
Highlights
Colorectal cancer (CRC) is the third most common cancer worldwide: each year, more than 500,000 cancer deaths are associated with this disease [1]
The goals of this study were as follows: (1) To assess CCE2 accuracy for colorectal neoplasia detection compared with conventional colonoscopy (CC)
We investigated the accuracy of CCE2 in terms of detecting polyps ≥ 6 mm, all polyps, polyps ≥ 10 mm, adenomas ≥ 10 mm, and cancers
Summary
Colorectal cancer (CRC) is the third most common cancer worldwide: each year, more than 500,000 cancer deaths are associated with this disease [1]. The National CRC Screening Program in the Czech Republic was launched in 2000. It is based on a fecal occult blood test (FOBT) offered to asymptomatic individuals aged ≥50 years. The program design was modified at the beginning of 2009 via the introduction of a screening colonoscopy offered to asymptomatic individuals older than 55. There is a need for other screening modalities with higher acceptance rates These modalities should adequately detect colorectal neoplasia and still be acceptable by the target population
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
